Baker Bros. Advisors LP Denali Therapeutics Inc. Transaction History
Baker Bros. Advisors LP
- $7.52 Billion
- Q2 2024
A detailed history of Baker Bros. Advisors LP transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 3,731,695 shares of DNLI stock, worth $110 Million. This represents 1.15% of its overall portfolio holdings.
Number of Shares
3,731,695
Previous 3,731,695
-0.0%
Holding current value
$110 Million
Previous $76.6 Million
13.16%
% of portfolio
1.15%
Previous 0.97%
Shares
9 transactions
Others Institutions Holding DNLI
# of Institutions
214Shares Held
121MCall Options Held
127KPut Options Held
38.3K-
Baillie Gifford & CO13.8MShares$405 Million0.25% of portfolio
-
Black Rock Inc. New York, NY13.2MShares$388 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.3MShares$333 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA9.82MShares$289 Million0.04% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.13MShares$210 Million0.04% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $3.95B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...